The Impact Of Thymectomy In Thymomatous And Nonthymomatous Myasthenia Gravis – The Experience Of A Tertiary Center
DOI:
https://doi.org/10.48729/pjctvs.328Keywords:
Myasthenia Gravis, Thymectomy, Thymoma, Nonthymomatous Myasthenia GravisAbstract
Introduction: Thymectomy remains a mainstay of treatment in Thymomatous (T) and Nonthymomatous (nT) Myasthenia Gravis (MG), with improved clinical outcomes and reduced need for medical treatment, however, there is little research regarding long-term follow-up. We aim to assess the impact of surgery on the long-term outcome of patients with MG at our center.Methods: Retrospective analyses of MG patients submitted to thymectomy between 2007 and 2017 at the thoracic surgery department of CHUC. Clinical assessment was performed according to the MG Foundation of America (MGFA) Clinical Classification (cMGFA). The follow-up was categorized according to the MGFA Post-intervention Status (MGFA-PIS) and cMGFA. Statistical analysis was performed with SPSS, to a significance level of 5%.
Results: Thirty-seven patients underwent extended thymectomy and 67.6% were female. Median age at diagnosis was 46.68±19.2 years. Most patients (83.8%) had anti-acetylcholine receptor antibodies and 81.1% had generalized forms of MG. Many patients (67.6%) had surgery less than 12 months after the clinical diagnosis. TMG was present in 19 (51.4%) patients. Compared to nTMG, these patients were older (54.06±17.9 vs 40.17±19.4 years) and most were men (52.9% vs 16.7%). We obtained a good outcome in most patients in the first (81.1%), second (86.1%), and fifth (84.8%) year of follow-up. There was a shift towards better prognosis categories in the good outcome group: 9.1% CSR, 3.0% PR, and 66,7% MM in the fifth year. Preoperative medical treatment did not influence the long-term follow-up outcome. A shorter time to surgery (< 12 months) correlated with better outcomes at year 5 (p=0.016).
Conclusion: Thymectomy led to a sustained clinical improvement in our cohort, allowing for a reduced need for medication. A shorter time to surgery seems to have a positive influence on long-term prognosis. We expect that an extended follow-up would improve our results.
Downloads
References
Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders: Autoimmune neuromuscular disorders. Eur J Neurol. 2010;17(7):893-902. doi:10.1111/j.1468-1331.2010.03019.x
Verschuuren JJGM, Huijbers MG, Plomp JJ, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;12(9):918-923. doi:10.1016/j.autrev.2013.03.001
Castleman B. THE PATHOLOGY OF THE THYMUS GLAND IN MYASTHENIA GRAVIS. Ann N Y Acad Sci. 1966;135(1 Myasthenia Gr):496-503. doi:10.1111/j.1749-6632.1966.tb45497.x
Blalock A, Mason MF, Morgan HJ, Riven SS. MYASTHENIA GRAVIS AND TUMORS OF THE THYMIC REGION: REPORT OF A CASE IN WHICH THE TUMOR WAS REMOVED. Ann Surg. 1939;110(4):544-561. doi:10.1097/00000658-19391000000005
Masaoka A, Yamakawa Y, Niwa H, et al. Extended Thymectomy for Myasthenia Gravis Patients: A 20-Year Review. Ann Thorac Surg. 1996;62(3):853-859. doi:10.1016/S0003-4975(96)00376-1
Faulkner SL, Ehyai A, Fisher RD, Fenichel GM, Bender HW. Contemporary Management of Myasthenia Gravis: The Clinical Role of Thymectomy. Ann Thorac Surg. 1977;23(4):348-352. doi:10.1016/S0003-4975(10)64139-2
Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016;375(6):511-522. doi:10.1056/NEJMoa1602489
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki A, Barohn RJ, et al. Myasthenia gravis: Recommendations for clinical research standards. Neurology. 2000;55(1):16-23. doi:10.1212/ WNL.55.1.16
Aprile V, Korasidis S, Bacchin D, et al. Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone. Ann Thorac Surg. 2021;112(6):1782-1789. doi:10.1016/j. athoracsur.2020.12.010
Frist WH, Thirumalai S, Doehring CB, et al. Thymectomy for the myasthenia gravis patient: Factors influencing outcome. Ann Thorac Surg. 1994;57(2):334-338. doi:10.1016/00034975(94)90993-8
Huang CS, Hsu HS, Huang BS, et al. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand. 2005;112(2):108-114. doi:10.1111/j.16000404.2005.00424.x
DrachmanDB.MyastheniaGravis.NEnglJMed.1994;330(25):1797-1810. doi:10.1056/NEJM199406233302507
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425. doi:10.1212/ WNL.0000000000002790
Gronseth GS, Barohn R, Narayanaswami P. Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2020;94(16):705-709. doi:10.1212/ WNL.0000000000009294
Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122. doi:10.1212/ WNL.0000000000011124
Dalakas MC. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies. Neurol - Neuroimmunol Neuroinflammation. 2022;9(1). doi:10.1212/ NXI.0000000000001116
Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76-83. doi:10.1196/annals.1405.012
Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122(3):562-568. doi:10.1067/mtc.2001.116191
Lin MW, Chang YL, Huang PM, Lee YC. Thymectomy for non-thymomatous myasthenia gravis: a comparison of surgical methods and analysis of prognostic factors. Eur J Cardiothorac Surg. 2010;37(1):7-12. doi:10.1016/j.ejcts.2009.05.027
Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7-15. doi:10.1212/wnl.55.1.7
López-Cano M, Ponseti-Bosch JM, Espin-Basany E, Sánchez-García JL, Armengol-Carrasco M. Clinical and pathologic predictors of outcome in Thymoma-Associated myasthenia gravis. Ann Thorac Surg. 2003;76(5):1643-1649. doi:10.1016/ S0003-4975(03)01139-1
Jaretzki A. Thymectomy for Myasthenia Gravis: Analysis of Controversies???Patient Management: The Neurologist. 2003;9(2):77-92. doi:10.1097/01.nrl.0000051446.03160.2e
Park IK, Choi SS, Lee JG, Kim DJ, Chung KY. Complete stable remission after extended transsternal thymectomy in myasthenia gravis. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2006;30(3):525-528. doi:10.1016/j.ejcts.2006.06.009
Downloads
Published
How to Cite
License
Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
This work is licensed under a Creative Commons Attribution 4.0 International License.
